BRAF and neoplasm: However, none of these candidate biomarkers has yet clearly proven to be useful for diagnosis or staging of patients with stage II colorectal cancer, except for mutations in the BRAF oncogene, which were found to be prognostic for overall survival, particularly in patients with microsatellite-stable tumours (French et al, 2008; Roth et al, 2010).